NO20080053L - Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid - Google Patents

Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid

Info

Publication number
NO20080053L
NO20080053L NO20080053A NO20080053A NO20080053L NO 20080053 L NO20080053 L NO 20080053L NO 20080053 A NO20080053 A NO 20080053A NO 20080053 A NO20080053 A NO 20080053A NO 20080053 L NO20080053 L NO 20080053L
Authority
NO
Norway
Prior art keywords
methylpyrazin
oxadiazol
pyridine
methoxy
phenyl
Prior art date
Application number
NO20080053A
Other languages
English (en)
Inventor
Catherine Good
Philip John Hogan
Frank Montgomery
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20080053L publication Critical patent/NO20080053L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

N-(3-Metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid-etanolaminsalt, syntese av dette samt anvendelser av det er beskrevet.
NO20080053A 2005-07-19 2008-01-04 Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid NO20080053L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514743.4A GB0514743D0 (en) 2005-07-19 2005-07-19 Salt
PCT/GB2006/002654 WO2007010235A1 (en) 2005-07-19 2006-07-17 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide

Publications (1)

Publication Number Publication Date
NO20080053L true NO20080053L (no) 2008-04-16

Family

ID=34897419

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080053A NO20080053L (no) 2005-07-19 2008-01-04 Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid

Country Status (23)

Country Link
US (2) US20080221124A1 (no)
EP (1) EP1904490B1 (no)
JP (1) JP5085544B2 (no)
KR (1) KR20080031042A (no)
CN (1) CN101223165B (no)
AT (1) ATE482952T1 (no)
AU (1) AU2006271420B2 (no)
CA (1) CA2615596A1 (no)
CY (1) CY1110942T1 (no)
DE (1) DE602006017220D1 (no)
DK (1) DK1904490T3 (no)
ES (1) ES2351442T3 (no)
GB (1) GB0514743D0 (no)
HK (1) HK1118276A1 (no)
HR (1) HRP20100621T1 (no)
IL (1) IL188389A0 (no)
MX (1) MX2008000889A (no)
NO (1) NO20080053L (no)
PL (1) PL1904490T3 (no)
PT (1) PT1904490E (no)
SI (1) SI1904490T1 (no)
WO (1) WO2007010235A1 (no)
ZA (1) ZA200800328B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0914287D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Compositions
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
DE60207890T2 (de) * 2001-12-18 2006-08-10 Astrazeneca Ab Neue verbindungen
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
CY1110942T1 (el) 2015-06-10
AU2006271420B2 (en) 2010-09-23
ES2351442T3 (es) 2011-02-04
ATE482952T1 (de) 2010-10-15
GB0514743D0 (en) 2005-08-24
MX2008000889A (es) 2008-03-18
DE602006017220D1 (de) 2010-11-11
HRP20100621T1 (hr) 2010-12-31
EP1904490B1 (en) 2010-09-29
JP2009501774A (ja) 2009-01-22
CN101223165B (zh) 2011-10-19
PL1904490T3 (pl) 2011-02-28
AU2006271420A1 (en) 2007-01-25
CN101223165A (zh) 2008-07-16
ZA200800328B (en) 2008-12-31
PT1904490E (pt) 2010-11-18
SI1904490T1 (sl) 2010-12-31
KR20080031042A (ko) 2008-04-07
US20080221124A1 (en) 2008-09-11
HK1118276A1 (en) 2009-02-06
EP1904490A1 (en) 2008-04-02
CA2615596A1 (en) 2007-01-25
US20120101109A1 (en) 2012-04-26
WO2007010235A8 (en) 2008-03-13
JP5085544B2 (ja) 2012-11-28
DK1904490T3 (da) 2010-12-13
IL188389A0 (en) 2008-04-13
WO2007010235A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
DK2358680T3 (da) Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
NO20070731L (no) Heterocykliske forbindelser.
HRP20090229T1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
RS50624B (sr) Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina
ATE459603T1 (de) Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4)
CY1112433T1 (el) Συνθεση ζιμποτεντανης που περιεχει μαννιτολη και μικροκρυσταλλικη κυτταρινη
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
RS50629B (sr) Amidni prolek gemcitabina, kompozicije i njihova primena
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
EA201070410A1 (ru) Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения
IL179346A0 (en) 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
NO20080053L (no) Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid
RS52351B (en) 5- (2,4-Dihydroxy-5-isopropyl-phenyl) -4- (4-morpholine-4-ylmethyl-phenyl) -isoxazole-3-carboxylic acid ethylamide mesylate, their hydrates and polymorphs, and formulations thereof
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
NO20064793L (no) Anvendelse av N-(2-arylpropionyl) sulfonamider for behandling av ryggmargskade.
WO2003047517A3 (en) Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application